EE04096B1 - Valitud lantaankarbonaathüdraate sisaldavad farmatseutilised kompositsioonid - Google Patents

Valitud lantaankarbonaathüdraate sisaldavad farmatseutilised kompositsioonid

Info

Publication number
EE04096B1
EE04096B1 EE9700325A EE9700325A EE04096B1 EE 04096 B1 EE04096 B1 EE 04096B1 EE 9700325 A EE9700325 A EE 9700325A EE 9700325 A EE9700325 A EE 9700325A EE 04096 B1 EE04096 B1 EE 04096B1
Authority
EE
Estonia
Prior art keywords
lanthanum carbonate
pharmaceutical compositions
compositions containing
pct
containing selected
Prior art date
Application number
EE9700325A
Other languages
English (en)
Estonian (et)
Other versions
EE9700325A (et
Inventor
Anthony Murrer Barry
Anthony Powell Nigel
Original Assignee
Johnson Matthey Public Limited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10771896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04096(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johnson Matthey Public Limited Company filed Critical Johnson Matthey Public Limited Company
Publication of EE9700325A publication Critical patent/EE9700325A/xx
Publication of EE04096B1 publication Critical patent/EE04096B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F17/00—Compounds of rare earth metals
    • C01F17/20—Compounds containing only rare earth metals as the metal element
    • C01F17/247—Carbonates
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Geology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EE9700325A 1995-03-25 1996-03-19 Valitud lantaankarbonaathüdraate sisaldavad farmatseutilised kompositsioonid EE04096B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9506126.3A GB9506126D0 (en) 1995-03-25 1995-03-25 Pharmaceutical composition and method
PCT/GB1996/000575 WO1996030029A1 (en) 1995-03-25 1996-03-19 Pharmaceutical composition containing selected lanthanum carbonate hydrates

Publications (2)

Publication Number Publication Date
EE9700325A EE9700325A (et) 1998-06-15
EE04096B1 true EE04096B1 (et) 2003-08-15

Family

ID=10771896

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700325A EE04096B1 (et) 1995-03-25 1996-03-19 Valitud lantaankarbonaathüdraate sisaldavad farmatseutilised kompositsioonid

Country Status (28)

Country Link
US (1) US5968976A (zh)
EP (1) EP0817639B1 (zh)
JP (1) JP3224544B2 (zh)
KR (1) KR100329340B1 (zh)
CN (1) CN1102393C (zh)
AT (1) ATE209923T1 (zh)
AU (1) AU702073B2 (zh)
BR (1) BR9607926A (zh)
CA (1) CA2216437C (zh)
CZ (1) CZ293494B6 (zh)
DE (4) DE69617659D1 (zh)
DK (1) DK0817639T3 (zh)
EA (1) EA000270B1 (zh)
EE (1) EE04096B1 (zh)
ES (1) ES2170223T3 (zh)
GB (1) GB9506126D0 (zh)
HK (1) HK1008182A1 (zh)
HU (1) HU224198B1 (zh)
MX (1) MX9707334A (zh)
NO (1) NO313488B1 (zh)
NZ (1) NZ303260A (zh)
PL (1) PL184315B1 (zh)
PT (1) PT817639E (zh)
SK (1) SK282607B6 (zh)
TR (1) TR199701030T1 (zh)
TW (1) TW436288B (zh)
WO (1) WO1996030029A1 (zh)
ZA (1) ZA962369B (zh)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
GB0015745D0 (en) 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
PT1389102E (pt) * 2001-04-23 2011-06-07 Shire Int Licensing Bv Utilização de carbonato de lantânio para a prevenção de cálculos renais
AU2003229437A1 (en) * 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
EP1647524A3 (en) * 2002-08-14 2006-09-13 Altair Nanomaterials Inc. Rare earth metal compounds, methods of making, and methods of using the same
CN100526219C (zh) * 2002-08-14 2009-08-12 爱尔达纳米公司 稀土金属化合物、其制造方法及其使用方法
SI2172205T1 (sl) * 2003-08-26 2014-10-30 Shire Biopharmaceuticals Holdings Ireland Limited Farmacevtska formulacija obsegajoča lantanove spojine
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
MX2007001114A (es) * 2004-07-27 2007-07-11 Shire Pharmaceuticals Inc Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano.
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
GB0502787D0 (en) * 2005-02-10 2005-03-16 Ineos Silicas Ltd Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
EP1698233A1 (en) * 2005-03-01 2006-09-06 Bayer HealthCare AG Reduction of digestibility of phosphorus in animal nutrition
ES2311443T1 (es) * 2005-08-17 2009-02-16 Altairnano, Inc Hiperfosfatemia en animales domesticos: composiciones y procedimientos de tratamiento.
WO2007022445A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
US20070259052A1 (en) * 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
ATE530896T1 (de) * 2006-05-05 2011-11-15 Shire Int Licensing Bv Assay für lanthan-hydroxycarbonat
CN101077338B (zh) * 2006-05-24 2012-06-20 天津大学 纳米碳酸镧口腔崩解片及制备方法
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) * 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
US8974824B2 (en) * 2008-03-26 2015-03-10 Mylan Laboratories Ltd. Lanthanum composition
CA2748496C (en) * 2009-01-21 2019-02-26 Mylan Inc. Disintegrable formulations of lanthanum carbonate
WO2010106557A2 (en) * 2009-03-20 2010-09-23 Panacea Biotec Limited Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof
BRPI0924533A2 (pt) * 2009-05-15 2015-06-30 Natco Pharma Ltd Processo para a preparação de carbonato de latânio di-hidratado
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
CA3224506A1 (en) 2010-05-12 2011-11-17 Unicycive Therapeutics, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
EP2441436A1 (de) * 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
WO2012098562A2 (en) 2011-01-19 2012-07-26 Panacea Biotec Limited Liquid oral compositions of lanthanum salts
CN102432055B (zh) * 2011-09-23 2013-10-16 北京大学 用于治疗高磷血症的碳酸镧纳米颗粒、其制备方法及用途
CN102442692B (zh) * 2011-09-23 2014-08-27 北京大学 碳酸镧水合物的制备方法
EA021712B1 (ru) * 2012-06-12 2015-08-31 Общество С Ограниченной Ответственностью "Рубикон" Противовоспалительное средство для лечения контактного дерматита
CN103251648B (zh) 2013-05-15 2015-08-05 乔敏 治疗血磷酸盐过多症及缺铁性贫血症的铁基蒙脱石药物及其制备方法
WO2016051609A1 (ja) * 2014-10-02 2016-04-07 東和薬品株式会社 粒度調整された炭酸ランタン水和物からなる医薬
CN104473963B (zh) * 2014-12-24 2017-10-10 厦门科明达科技有限公司 稀土化学药碳酸镧咀嚼片的制备方法
US10058569B2 (en) * 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
CN105125575B (zh) * 2015-08-07 2018-06-08 康臣药业(内蒙古)有限责任公司 一种治疗高磷酸盐血症药物的制备方法
CA3001444A1 (en) 2015-11-30 2017-06-08 Toray Industries, Inc. Phosphorus adsorbent, porous fiber and phosphorus adsorption column
CN107876000A (zh) * 2017-10-30 2018-04-06 浙江大学 一种纳米除磷剂、制备方法及应用
CN110579499A (zh) * 2018-06-08 2019-12-17 北京华睿鼎信科技有限公司 一种碳酸镧或其制剂中碱式碳酸镧杂质的检定方法
MX2021004516A (es) * 2018-10-26 2021-06-15 Sumitomo Chemical Co Metodo para produccion de hidrato de carbonato de lantano.
CN111620363A (zh) * 2020-06-13 2020-09-04 南京卡文迪许生物工程技术有限公司 一种四水合碳酸镧的制备方法及其产品
AU2021309295A1 (en) 2020-07-13 2023-03-09 Applause Pharma Co., Ltd. Pharmaceutical composition containing cerium compound as active ingredient
CN114477265B (zh) * 2020-11-13 2023-11-03 南京正济医药研究有限公司 一种四水碳酸镧的制备方法
CN115849429B (zh) * 2023-01-06 2024-01-23 湖南明瑞制药股份有限公司 一种小粒径四水碳酸镧的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06705B2 (ja) * 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤

Also Published As

Publication number Publication date
WO1996030029A1 (en) 1996-10-03
CA2216437A1 (en) 1996-10-03
NZ303260A (en) 2000-01-28
JPH11503119A (ja) 1999-03-23
CZ293494B6 (cs) 2004-05-12
DE122007000022I1 (de) 2007-07-12
GB9506126D0 (en) 1995-05-10
KR19980703280A (ko) 1998-10-15
CN1184428A (zh) 1998-06-10
NO974425D0 (no) 1997-09-24
PL322450A1 (en) 1998-02-02
MX9707334A (es) 1998-07-31
ZA962369B (en) 1996-11-18
SK282607B6 (sk) 2002-10-08
SK128897A3 (en) 1998-10-07
DE69617659T4 (de) 2007-09-27
DE122007000022I2 (de) 2009-09-17
EA000270B1 (ru) 1999-02-25
NO313488B1 (no) 2002-10-14
EP0817639A1 (en) 1998-01-14
CA2216437C (en) 2002-10-22
TW436288B (en) 2001-05-28
DK0817639T3 (da) 2002-04-02
TR199701030T1 (xx) 1998-06-22
HK1008182A1 (en) 1999-05-07
HU224198B1 (hu) 2005-06-28
HUP9900799A2 (hu) 1999-09-28
EP0817639B1 (en) 2001-12-05
EA199700266A1 (ru) 1998-02-26
CN1102393C (zh) 2003-03-05
JP3224544B2 (ja) 2001-10-29
AU4951496A (en) 1996-10-16
DE69617659D1 (de) 2002-01-17
PL184315B1 (pl) 2002-10-31
DE69617659T2 (de) 2002-10-02
AU702073B2 (en) 1999-02-11
ES2170223T3 (es) 2002-08-01
NO974425L (no) 1997-11-24
CZ301797A3 (cs) 1998-07-15
EE9700325A (et) 1998-06-15
BR9607926A (pt) 1998-06-09
ATE209923T1 (de) 2001-12-15
PT817639E (pt) 2002-05-31
KR100329340B1 (ko) 2002-06-20
US5968976A (en) 1999-10-19
HUP9900799A3 (en) 2000-10-30

Similar Documents

Publication Publication Date Title
EE9700325A (et) Valitud lantaankarbonaathüdraate sisaldavad farmatseutilised kompositsioonid
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
IS4397A (is) Ný lyfjablanda til meðhöndlunar á verkjum sem inniheldur staðdeyfiefni, skautuð lípíð og tríasýlglýseról
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
NO964486L (no) Anvendelse av visse metanbisfosfonsyrederivater for å forhindre lösning av protese og protesemigrering
DE69531098D1 (de) Piperidine und pyrrolidine
SE9402880D0 (sv) New peptide derivatives
MA22343A1 (fr) Compositions type massepain, contenant du psyllium
FI963394A (fi) Yskää vastustava koostumus, joka sisältää yskää vastustavaa ainetta ja bentsydamiinia
FI963567A (fi) Diklofenakki-Na:a sisältävä depottabletti
BR0207446A (pt) Composição medicinal que contém diclofenaco e ornoprostil.
ZA905422B (en) Substituted 2-imidazolines and preparation and use thereof
MY128686A (en) Pharmaceutical composition containing selected lanthanum carbonate hydrates
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
ATE187068T1 (de) Mikrogranulate enthaltend 5-nitroimidazolderivate
UA37820A (uk) Спосіб лікування виразкової хвороби дванадцятипалої кишки у осіб похилого та старечого віку

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

GB1A Change in the ownership or in the address of the owner

Owner name: SHIRE INTERNATIONAL LICENSING BV, NL

Free format text: FORMER OWNER: ANORMED INC., CA

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231